A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)

Trial Profile

A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Raxibacumab (Primary) ; Anthrax vaccine; Diphenhydramine; Diphenhydramine
  • Indications Anthrax; Bacterial infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 19 Sep 2016 Planned End Date changed from 1 Aug 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top